Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218196 | 0.85 | MAOA (0.55) | MAOAMAOB | |
| SCHEMBL578027 | 0.84 | MAOA (0.59) | MAOAMAOB | |
| SCHEMBL216450 | 0.82 | MAOA (0.42) | MAOAMAOB | |
| SCHEMBL214352 | 0.81 | MAOA (0.46) | MAOAMAOB | |
| SCHEMBL9776303 | 0.78 | ALDH1A1 (0.43) | — | |
| SCHEMBL578471 | 0.77 | ALDH1A1 (0.34) | — | |
| SCHEMBL217306 | 0.76 | DRD2 (0.48) | MAOAMAOB | |
| SCHEMBL21591607 | 0.74 | CYP2D6 (0.33) | — | |
| SCHEMBL5523407 | 0.72 | CYP11B2 (0.36) | — | |
| SCHEMBL4137719 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | REGOR PHARMACEUTICALS, INC. | 2022-12-08 | — | — | US | disclosed |
| CN-114555585-A | HPK1 inhibitors and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-3994133-A1 | HPK1 INHIBITORS AND USES THEREOF | Qilu Regor Therapeutics Inc. (CN) | 2022-05-11 | — | — | EP | disclosed |
| WO-2021000935-A1 | HPK1 INHIBITORS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021000855-A1 | MALT1 INHIBITORS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020206583-A1 | KINASE INHIBITORS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-10-15 | — | — | WO | disclosed |
| US-RE47731-E1 | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK (CA) | 2019-11-19 | — | — | US | disclosed |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2019-07-23 | — | — | US | disclosed |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-04 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8263596-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2012-09-11 | — | — | US | disclosed |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORKS (CA) | 2012-06-14 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2011-10-27 | — | — | US | disclosed |
| WO-2011123947-A1 | SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'- INDOLIN]-2'-ONES | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011123946-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2011-10-13 | — | — | WO | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389037-A1 | HPK1 INHIBITORS AND USES THEREOF | HIPK1, SIK1, PGK1 | MAOA 4363/4885MAOB 4431/4885 |
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | MAOA 2774/4885MAOB 2654/4885 |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | MAOA 2530/4885MAOB 2002/4885 |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | MAOA 2327/4885MAOB 1829/4885 |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | MAP3K6, MAP3K5, MAP3K19 | MAOA 2327/4885MAOB 1829/4885 |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | MAOA 2327/4885MAOB 1829/4885 |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | MAOA 2305/4885MAOB 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.